ImmunoGen Value Stock - Dividend - Research Selection
Immunogen
ISIN: US45253H1014 , WKN: 878613
Market price date:
Market price:
Market price:
Fundamental data and company key figures of the share
| Annual reports in | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Key figures | |||||||||||||||||||||||||||||||||||||||||||||||||
| Cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net operating cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Capital Expenditures | |||||||||||||||||||||||||||||||||||||||||||||||||
| Free cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Balance sheet | |||||||||||||||||||||||||||||||||||||||||||||||||
| Total Equity | |||||||||||||||||||||||||||||||||||||||||||||||||
| Liabilities & Shareholders equity | |||||||||||||||||||||||||||||||||||||||||||||||||
| Income statement | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | |||||||||||||||||||||||||||||||||||||||||||||||||
| Eps (diluted) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Diluted shares outstanding | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net sales/revenue | |||||||||||||||||||||||||||||||||||||||||||||||||
Do you want to do make a detailed fundamental analysis of this stock?
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
| Description | Data |
|---|---|
| Symbol | |
| Market Capitalization | USD |
| Country | |
| Indices | |
| Sectors | |
| Raw Data Source | |
| Stock Split | |
| Internet |
Description of the company
ImmunoGen, Inc., a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Jazz Pharmaceuticals plc; and Debiopharm International SA. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,
NEWS
Q4 2022 ImmunoGen Inc Earnings Call
2023-03-02
Q4 2022 ImmunoGen Inc Earnings Call
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-03-01
WALTHAM, Mass., March 01, 2023--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImmunoGen Allows Vertex Pharma Use Its Technology For Conditioning Agents For Use With Gene Editing
2023-03-01
ImmunoGen Inc (NASDAQ: IMGN) announced a global, multi-target license and option agreement that granted Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) rights for ImmunoGen's ADC technology to discover targeted conditioning agents for use with gene editing. After each target's research period, Vertex will have the option to obtain a worldwide, exclusive license to research, develop, and commercialize conditioning agents employing ImmunoGen's technology for that target. ImmunoGen will retain f
ImmunoGen (IMGN) Reports Q4 Loss, Tops Revenue Estimates
2023-03-01
ImmunoGen (IMGN) delivered earnings and revenue surprises of 20.69% and 132.98%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ImmunoGen Reports Recent Progress and 2022 Financial Results
2023-03-01
WALTHAM, Mass., March 01, 2023--ImmunoGen Reports Recent Progress and 2022 Financial Results
ImmunoGen Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning Agents
2023-03-01
WALTHAM, Mass., March 01, 2023--ImmunoGen Announces Global, Multi-Target Agreement with Vertex for Use of ImmunoGen's ADC Tech for Development of Novel Targeted Conditioning Agents
ImmunoGen, Inc. (IMGN) Q4 2022 Earnings Call Transcript
2023-03-01
ImmunoGen, Inc. (NASDAQ:NASDAQ:IMGN) Q4 2022 Earnings Conference Call March 1, 2023 8:00 AM ETCompany ParticipantsAnabel Chan - Head, IRMark Enyedy - President and CEOAnna Berkenblit -...
Unusually active option classes on open March 1st
2023-03-01
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
ImmunoGen: Q4 Earnings Snapshot
2023-03-01
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
ImmunoGen beats Q4 top and bottom line estimates; initiates FY23 outlook
2023-03-01
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.